Crews Bank & Trust’s Jazz Pharmaceuticals JAZZ Stock Holding History

Crews Bank & Trust’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2	Closed	-$212	–	646
2025 Q2	$212	Buy	+2	New	+$217	﹤0.01%	616

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Crews Bank & Trust's JAZZ Position: Q3 2025 in Review

Crews Bank & Trust sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 2 shares — an estimated $212 sold.

Crews Bank & Trust first reported a position in JAZZ in Q2 2025 and held it in 1 quarter. The position peaked at $212 in Q2 2025. 503 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

Crews Bank & Trust reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Crews Bank & Trust sold 2 Jazz Pharmaceuticals shares in Q3 2025, an estimated $212.
Crews Bank & Trust first reported a position in Jazz Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Crews Bank & Trust's Jazz Pharmaceuticals position peaked at $212 in Q2 2025.
503 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on Crews Bank & Trust's 13F filing for Q3 2025, filed 22 Oct 2025.